Dyadic International, Inc. (DYAI) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Dyadic International, Inc. (d/b/a Dyadic Applied BioSolutions) is a biotechnology platform company focused on developing scalable, non-animal protein production platforms (Dapibus™ and C1) for life sciences, food, nutrition, and bio-industrial markets. The company operates as a single segment and is headquartered in Jupiter, Florida, with operations in the Netherlands.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $1,164,617 | $1,957,500 | $2,524,819 | $2,678,013 |
| Net Loss | $(1,976,012) | $(203,460) | $(5,797,365) | $(4,258,279) |
| Loss Per Share (Basic/Diluted) | $(0.06) | $(0.01) | $(0.17) | $(0.15) |
| Cash & Equivalents (Total) | $7,155,788 (as of Sept 30, 2025) | |||
| Investment Securities | ||||
| Convertible Notes (Principal) | $5,090,000 Outstanding (Related Party: $2.09M; Third Party: $3.0M) | |||
| Operating Cash Flow (YTD) | $(3,932,110) | $(3,278,411) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 40.5% in Q3 2025 compared to Q3 2024, primarily due to a reduction in active research collaborations (from 10 to 4) and the absence of significant license/milestone revenue recognized in the current quarter. Grant revenue of $814,571 in Q3 2025 (from Gates Foundation and CEPI) partially offset the decline in R&D revenue.
- Increased Loss: Net loss widened significantly to $1.98 million in Q3 2025 from $0.20 million in Q3 2024. This was driven by lower revenue, increased costs of grant revenue ($769k), and higher general and administrative expenses related to rebranding and business development.
- Capital Raise: In August 2025, the company completed an underwritten public offering of 6,052,000 shares at $0.95 per share, raising net proceeds of approximately $4.9 million. This contrasts with Q3 2024, which saw no equity financing.
- Debt Structure: The company amended its Convertible Notes in May and September 2025, extending the redemption date to December 1, 2026. Related party holdings of the notes increased following a $1 million assignment to the CEO's trust.
Outlook, Risks, and Management Commentary
- Liquidity: Management expects existing cash, cash equivalents, restricted cash, and investment securities (totaling approx. $10.4 million) to be sufficient for operations for at least the next 12 months. However, the company continues to incur losses and expects negative operating cash flows.
- Commercialization: The company is transitioning from a research-driven organization to a commercially focused enterprise. Key milestones include the receipt of a $250,000 milestone payment from Inzymes in June 2025 and a $500,000 milestone from Proliant in October 2025 (subsequent to quarter end).
- Grants: Significant non-dilutive funding includes a $3.1 million grant from the Gates Foundation (approx. $2.4M received) and a $4.5 million grant from CEPI (Dyadic eligible for up to $2.4M).
- Risks:
- Going Concern: While liquidity is currently adequate, the company has a history of net losses and relies on future capital raises or commercialization success.
- Nasdaq Compliance: The company previously received deficiency notices regarding Market Value of Listed Securities (MVLS) and Minimum Bid Price but has since cured these deficiencies and regained compliance.
- Customer Concentration: Three customers accounted for 73% of Q3 2025 revenue. Loss of these customers could materially impact operations.
Investor Verification Checklist
- Verify the status and funding schedule of the Gates Foundation and CEPI grants, as these represent a significant portion of current revenue.
- Monitor the commercialization timeline for the Proliant (Serum Albumin) and Inzymes (Dairy Enzymes) partnerships, specifically the expected launch dates in late 2025/early 2026.
- Review the terms of the Convertible Notes, specifically the redemption date of December 1, 2026, and the conversion price of $1.40 per share.
- Assess the impact of the recent public offering on share dilution and the company's runway given the continued operating losses.
- Confirm ongoing compliance with Nasdaq listing standards following the recent cure of deficiencies.